Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

DIASORIN MOLECULAR

DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products on the versatile LIAISON... read more Featured Products: More products

Download Mobile App





Diasorin Launches New Assay for Rapid Identification of SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 25 May 2021
DiaSorin Molecular LLC (‎Cypress, CA, USA) has released the Simplexa SARS-CoV-2 Variants Direct assay (RUO) to enable detection and discrimination of four SARS-CoV-2 mutations associated with circulating virus variants without requiring upfront RNA extraction. More...


The assay helps to streamline and speed-up the pre-selection process of positive samples that need further sequencing, maximizing the effectiveness of monitoring programs for the spread of concerning variants. The Simplexa SARS-CoV-2 Variants Direct is a Research Use Only assay and is not for use in diagnostics procedures. The assay allows for the in vitro qualitative differential detection of the mutations N501Y, E484K, E484Q, and L452R directly from nasopharyngeal and nasal swab specimens from individuals previously diagnosed with COVID-19. These mutations are present in potential variants of clinical interest including those that were isolated in the UK (B.1.1.7), South Africa (B.1.351), Brazil/Japan (P.1 and P.2), New York (B.1.526/B.1.526.1), California (B.1.427/B.1.429), Nigeria (B.1.525) and India (B.1.617/B.1.617.1/B.1.617.2/B.1.617.3).

The kit format consists of pre-aliquoted reagents that are ready for use while leveraging Direct Amplification Disc technology and the melting curve capabilities of the LIAISON MDX. During the course of the COVID-19 pandemic, new genetic variants of SARS-CoV-2 have spread rapidly across the globe, creating concern as to their infectivity, transmissibility, and the impact on current vaccines or available immunotherapy. The availability of affordable molecular solutions that can be easily implemented and provide quick results will facilitate and increase the ability to monitor the spread of variants by streamlining laboratory workflows.

“The ability to identify potential SARS-CoV-2 variants in positive samples is of national and global importance in the continuous effort to monitor, track, and fight against SARS-CoV-2 variants,” said John Gerace, president of DiaSorin Molecular. “We are proud to continually develop products that meet the evolving needs of laboratories around the globe during this time.”





Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.